tradingkey.logo

CMS' support for blood pressure procedure a win for Medtronic, say analysts

ReutersJul 11, 2025 10:25 AM

Shares of medical device maker Medtronic MDT.N rise 3% to $92.16 premarket

Late on Thursday, the Centers for Medicare & Medicaid Services released a memosupporting insurance coverage for renal denervation (RDN) procedures, which are used to treat high blood pressure

Brokerage BTIG says this is a "win" for Medtronic who has been preparing hospitals for coverage with the launch of its Symplicity Spyral renal denervation device

"We came away encouraged by the proposed coverage for a broader patient population" says brokerage Leerink Partners

RBC Capitals Markets says this indicates MDT's potential to tap into the vast market, giving them further confidence in the durability of co's revenue growth profile

Up to last close, stock was up 12% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI